AU6432094A - Staple and semi-staple oligonucleotides, method of preparation and applications - Google Patents

Staple and semi-staple oligonucleotides, method of preparation and applications

Info

Publication number
AU6432094A
AU6432094A AU64320/94A AU6432094A AU6432094A AU 6432094 A AU6432094 A AU 6432094A AU 64320/94 A AU64320/94 A AU 64320/94A AU 6432094 A AU6432094 A AU 6432094A AU 6432094 A AU6432094 A AU 6432094A
Authority
AU
Australia
Prior art keywords
staple
semi
applications
preparation
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64320/94A
Inventor
Marta Blumenfeld
Said Meguenni
Bruno Poddevin
Marc Vasseur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Publication of AU6432094A publication Critical patent/AU6432094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU64320/94A 1993-03-26 1994-03-25 Staple and semi-staple oligonucleotides, method of preparation and applications Abandoned AU6432094A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9303514 1993-03-26
FR9303514A FR2703053B1 (en) 1993-03-26 1993-03-26 STAPLE AND SEMI-STAPLE OLIGONUCLEOTIDES, PREPARATION METHOD AND APPLICATIONS.
PCT/FR1994/000336 WO1994023026A1 (en) 1993-03-26 1994-03-25 Staple and semi-staple oligonucleotides, method of preparation and applications

Publications (1)

Publication Number Publication Date
AU6432094A true AU6432094A (en) 1994-10-24

Family

ID=9445387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64320/94A Abandoned AU6432094A (en) 1993-03-26 1994-03-25 Staple and semi-staple oligonucleotides, method of preparation and applications

Country Status (3)

Country Link
AU (1) AU6432094A (en)
FR (1) FR2703053B1 (en)
WO (1) WO1994023026A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022114A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. PRODUCTION OF ssDNA $i(IN VIVO)
FR2732971B1 (en) * 1995-04-13 1997-07-04 Genset Sa OLIGONUCLEOTIDE SENSE INHIBITOR OF HERPES SIMPLEX VIRUS (HSV) WITH HALTERED STRUCTURE
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050059016A1 (en) * 2002-11-05 2005-03-17 Ecker David J. Structural motifs and oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
DE19631919C2 (en) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-sense RNA with secondary structure
WO2000022113A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. ENZYMATIC SYNTHESIS OF ssDNA
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
FR2790757B1 (en) 1999-03-09 2003-08-01 Bioalliance Pharma OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
CA2408326A1 (en) * 2000-06-23 2002-01-03 E.I. Dupont De Nemours And Company Recombinant constructs and their use in reducing gene expression
US7358066B2 (en) 2001-07-24 2008-04-15 Serono Genetics Institute S.A. Variants and exons of the GlyT1 transporter
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2005030960A1 (en) * 2003-09-30 2005-04-07 Anges Mg, Inc. Staple type oligonucleotide and drug comprising the same
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
MX2007008065A (en) * 2004-12-30 2008-03-04 Todd M Hauser Compositions and methods for modulating gene expression using self-protected oligonucleotides.
WO2007095387A2 (en) 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379369B1 (en) * 1989-01-19 1996-09-04 BEHRINGWERKE Aktiengesellschaft Nucleic acid amplification using single primer
NO904633L (en) * 1989-11-09 1991-05-10 Molecular Diagnostics Inc AMPLIFICATION OF NUCLEIC ACIDS BY TRANSCRIPABLE HAIRNEL PROBE.
WO1991017246A1 (en) * 1990-05-04 1991-11-14 Isis Pharmaceuticals, Inc. Modulation of gene expression through interference with rna secondary structure
IL99069A (en) * 1990-08-09 1998-08-16 Genta Inc Psoralen conjugated methylphosphonate oligonucleotides
FR2675803B1 (en) * 1991-04-25 1996-09-06 Genset Sa CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS.
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides

Also Published As

Publication number Publication date
WO1994023026A1 (en) 1994-10-13
FR2703053B1 (en) 1995-06-16
FR2703053A1 (en) 1994-09-30

Similar Documents

Publication Publication Date Title
AU6432094A (en) Staple and semi-staple oligonucleotides, method of preparation and applications
EP0710667B8 (en) Modified oligonucleotides, their preparation and their use
AU1108695A (en) Aza-4-iminoquinolines, methods of preparing them and their use
AU6498694A (en) Dihydropyridines and new uses thereof
AU679663B2 (en) Dermatological or pharmaceutical composition, preparation process and use
AU1581895A (en) Nucleic acid-containing composition, its preparation and use
AU5724396A (en) Chemical ligation of template-directed oligonucleotides
AU3104597A (en) Phosphotriester oligonucleotides, amidites and method of preparation
AU1925195A (en) Nucleic acid delivery system, method of synthesis and uses thereof
AU5422696A (en) Nox catalyst and method of using the same
AU7125996A (en) Micro-mixer and mixing method
AU4826196A (en) Cyclic compounds, their production and use
AU4093497A (en) Silane-treated clay production method, silane-treated clay and composition containing same
AU4911496A (en) Multiple component rna catalysts and uses thereof
AU5983696A (en) Fragile x related proteins, compositions and methods of maki ng and using the same
AU7095296A (en) Phosphorylamides, their preparation and use
AU1054795A (en) Method of forming self-texturing filaments and resulting self-texturing filaments
AU5376996A (en) Low temperature composition preparation device, and methods of constructing and utilizing same
AU679275B2 (en) Particulate explosive, manufacturing method and use
AU5922694A (en) 2-amino-4-quinolyl-dihydropyridines, processes for their preparation, and their use
AU5798996A (en) Adnaz, compositions and processes
AU3473695A (en) Novel 4-aminopyridazines, method of preparing them and drugs containing these compounds
AU9569998A (en) Photo-spectrometers, methods of use and manufacture
AU1314995A (en) Aminosulphonyl-phenyl-1h-pyrrole derivatives, method of their preparation and their use
AU673401B2 (en) 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound